文献速递肾移植

药师主导的移动健康干预与移植用药安全:一项随机对照临床试验

Pharmacist-Led Mobile Health Intervention and Transplant Medication Safety: A Randomized Controlled Clinical Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2021-04-30

这项为期12个月的单中心随机对照试验纳入136例肾移植受者,评估药师主导的移动健康干预对用药安全的影响。干预组接受基于移动健康应用的药物治疗监测与管理,并整合风险导向的视频访视及居家血压和血糖监测。结果显示干预组用药错误风险率降低61%,3级及以上不良事件发生风险显著降低,住院率显著降低。

要点

  • 药师主导的移动健康干预可显著降低肾移植受者用药错误风险(风险率降低61%)。
  • 干预组3级及以上不良事件发生风险显著低于对照组(IRR 0.55)。
  • 干预组住院率显著低于对照组(IRR 0.46)。

核心结论

  • 药师主导的移动健康干预显著降低了肾移植受者的用药错误、不良事件和住院率。

研究设计与样本

  • 12个月、单中心、前瞻性、平行两组、单盲随机对照试验,纳入136例成人肾移植受者(每组68例),移植后6-36个月。

主要发现

  • 干预组用药错误风险率降低61%(IRR 0.39,95%CI 0.28-0.55,P<0.001)。
  • 干预组3级及以上不良事件发生风险显著降低(IRR 0.55,95%CI 0.30-0.99,P=0.05)。
  • 干预组住院率显著降低(IRR 0.46,95%CI 0.27-0.77,P=0.005)。

临床怎么用

  • 对于移植后6-36个月的肾移植受者,可考虑采用药师主导的移动健康干预以提升用药安全。

局限性

  • 单中心研究,样本量有限,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Medication safety events are predominant contributors to suboptimal graft outcomes in kidney transplant recipients. The goal of this study was to examine the efficacy of improving medication safety through a pharmacist-led, mobile health-based intervention. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a 12-month, single-center, prospective, parallel, two-arm, single-blind, randomized controlled trial. Adult kidney recipients 6-36 months post-transplant were eligible. Participants randomized to intervention received supplemental clinical pharmacist-led medication therapy monitoring and management via a mobile health-based application, integrated with risk-guided televisits and home-based BP and glucose monitoring. The application provided an accurate medication regimen, timely reminders, and side effect surveys. Both the control and intervention arms received usual care, including serial laboratory monitoring and regular clinic visits. The coprimary outcomes were to assess the incidence and severity of medication errors and adverse events. RESULTS: In total, 136 kidney transplant recipients were included, 68 in each arm. The mean age was 51 years, 57% were male, and 64% were Black individuals. Participants receiving the intervention experienced a significant reduction in medication errors (61% reduction in the risk rate; incident risk ratio, 0.39; 95% confidence interval, 0.28 to 0.55; P<0.001) and a significantly lower incidence risk of Grade 3 or higher adverse events (incident risk ratio, 0.55, 95% confidence interval, 0.30 to 0.99; P=0.05). For the secondary outcome of hospitalizations, the intervention arm demonstrated significantly lower rates of hospitalizations (incident risk ratio, 0.46; 95% confidence interval, 0.27 to 0.77; P=0.005). CONCLUSIONS: We demonstrated a significant reduction in medication errors, adverse events, and hospitalizations using a pharmacist-led, mobile health-based intervention.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Gonzales HM, Fleming JN, Gebregziabher M, et al. Pharmacist-Led Mobile Health Intervention and Transplant Medication Safety: A Randomized Controlled Clinical Trial. Clin J Am Soc Nephrol. 2021. PMID: 33931415. doi:10.2215/CJN.15911020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。